89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer
Authors
Keywords
-
Journal
NATURE MEDICINE
Volume 24, Issue 12, Pages 1852-1858
Publisher
Springer Nature
Online
2018-11-20
DOI
10.1038/s41591-018-0255-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Atezolizumab (MPDL3280A) Monotherapy for Patients With Metastatic Urothelial Cancer
- (2018) Daniel P. Petrylak et al. JAMA Oncology
- Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
- (2017) Arjun V Balar et al. LANCET
- Heterogeneous expression of PD-L1 in pulmonary squamous cell carcinoma and adenocarcinoma: implications for assessment by small biopsy
- (2017) Thomas J Gniadek et al. MODERN PATHOLOGY
- Tumor mutation load assessed by FoundationOne (FM1) is associated with improved efficacy of atezolizumab (atezo) in patients with advanced NSCLC
- (2016) M. Kowanetz et al. ANNALS OF ONCOLOGY
- Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure)
- (2016) J. M. Kim et al. ANNALS OF ONCOLOGY
- The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition
- (2016) P. S. Hegde et al. CLINICAL CANCER RESEARCH
- Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma
- (2016) Zhong-Yi Dong et al. CLINICAL CANCER RESEARCH
- Quantitative and qualitative characterization of Two PD-L1 clones: SP263 and E1L3N
- (2016) Jacquelyn Smith et al. Diagnostic Pathology
- Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study
- (2016) David F. McDermott et al. JOURNAL OF CLINICAL ONCOLOGY
- Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma
- (2016) Adil I. Daud et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
- (2016) Louis Fehrenbacher et al. LANCET
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Quantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer
- (2016) Jamaal A Rehman et al. MODERN PATHOLOGY
- Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas
- (2016) Andreas H Scheel et al. MODERN PATHOLOGY
- Resolution of inflammation: a new therapeutic frontier
- (2016) James N. Fullerton et al. NATURE REVIEWS DRUG DISCOVERY
- Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade
- (2016) P.-L. Chen et al. Cancer Discovery
- A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors
- (2016) Samit Chatterjee et al. Oncotarget
- Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer
- (2016) Joseph McLaughlin et al. JAMA Oncology
- Noninvasive Imaging of Tumor PD-L1 Expression Using Radiolabeled Anti-PD-L1 Antibodies
- (2015) S. Heskamp et al. CANCER RESEARCH
- ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody-Drug Conjugate Treatment
- (2015) L. E. Lamberts et al. CLINICAL CANCER RESEARCH
- Antibody Positron Emission Tomography Imaging in Anticancer Drug Development
- (2015) Laetitia E. Lamberts et al. JOURNAL OF CLINICAL ONCOLOGY
- TGF- Antibody Uptake in Recurrent High-Grade Glioma Imaged with 89Zr-Fresolimumab PET
- (2015) M. W. den Hollander et al. JOURNAL OF NUCLEAR MEDICINE
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
- (2015) E. M. Van Allen et al. SCIENCE
- Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies
- (2015) Peter C. Austin et al. STATISTICS IN MEDICINE
- Inducible Expression of B7-H1 (PD-L1) and Its Selective Role in Tumor Site Immune Modulation
- (2014) Miguel F. Sanmamed et al. CANCER JOURNAL
- 89Zr-trastuzumab and 89Zr-bevacizumab PET to Evaluate the Effect of the HSP90 Inhibitor NVP-AUY922 in Metastatic Breast Cancer Patients
- (2014) S. B. M. Gaykema et al. CLINICAL CANCER RESEARCH
- Immune Checkpoint Inhibitors in NSCLC
- (2014) Douglas B. Johnson et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- ImmunoPET and biodistribution with human epidermal growth factor receptor 3 targeting antibody89Zr-RG7116
- (2014) Anton GT Terwisscha van Scheltinga et al. mAbs
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
- (2014) Thomas Powles et al. NATURE
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials
- (2014) Jason Madore et al. Pigment Cell & Melanoma Research
- Repeatability of Metabolically Active Tumor Volume Measurements with FDG PET/CT in Advanced Gastrointestinal Malignancies: A Multicenter Study
- (2014) Virginie Frings et al. RADIOLOGY
- Multicenter Harmonization of 89Zr PET/CT Performance
- (2013) N. E. Makris et al. JOURNAL OF NUCLEAR MEDICINE
- SIRP /CD172a and FHOD1 Are Unique Markers of Littoral Cells, a Recently Evolved Major Cell Population of Red Pulp of Human Spleen
- (2012) J. G. Ogembo et al. JOURNAL OF IMMUNOLOGY
- PET with the 89Zr-Labeled Transforming Growth Factor- Antibody Fresolimumab in Tumor Models
- (2011) T. H. Oude Munnink et al. JOURNAL OF NUCLEAR MEDICINE
- Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast Cancer
- (2010) E C Dijkers et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More